Tofacitinib
Tofacitinib is a small-molecule Janus kinase inhibitor targeting JAK1 and JAK3 with some activity against JAK2, blocking the downstream signal transducer and activator of transcription (STAT) pathways.
Tofacitinib is a small-molecule Janus kinase inhibitor targeting JAK1 and JAK3 with some activity against JAK2, blocking the downstream signal transducer and activator of transcription (STAT) pathways. That pairing matters mechanistically: JAK3 associates exclusively with the common gamma chain, so inhibiting the JAK1/JAK3 combination shuts down the interleukin-2, -4, -7, -9, -15 and -21 signals that drive lymphocyte activation, while tofacitinib-mediated JAK2 inhibition accounts for the anemia and cytopenias seen at higher exposure, since JAK2 carries erythropoietin and thrombopoietin signaling. Classified under ATC code L04, it was among the first oral JAK inhibitors approved for clinical use, a targeted immunotherapy that interrupts JAK/STAT-mediated cytokine signaling — including pathways driven by proinflammatory interleukins and interferons — suppressing the immune activation central to immune-mediated inflammatory diseases. Being a small molecule with a short half-life given twice daily, it differs practically from biologics such as adalimumab, etanercept and rituximab, which are injected, act on a single extracellular target, and persist for weeks: JAK inhibition can be stopped quickly when infection appears, but covers many cytokines at once rather than one.
It is approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis (UC), and has been investigated off-label across numerous dermatologic and inflammatory conditions, including ankylosing spondylitis. As a first-generation agent it sits alongside newer, more selective ones such as upadacitinib, baricitinib, abrocitinib and deucravacitinib.
Its safety profile has shaped the entire class. A post-authorization trial in rheumatoid arthritis patients over 50 with a cardiovascular risk factor, comparing tofacitinib against Tnf inhibitors, found higher rates of major adverse cardiovascular events and malignancy — the basis of boxed warnings now applied across JAK inhibitors, alongside serious infection and thrombosis. Herpes zoster reactivation is characteristic and notably more frequent than with biologics. The findings have restricted use in many settings to patients who have failed a Tnf inhibitor, and continue to drive real-world safety research.
Where the papers sit
11 papers from the last 6 months study tofacitinib directly · updated from PubMed 12 Nov 2026
Study type 2 clinical trials · 5 observational · 1 human data · 3 preclinical
Themes 3 themes
-
JAK Therapy in Rheumatoid Arthritis
Rheumatoid arthritis JAK inhibition is being assessed across effectiveness, treatment persistence, vascular biology, interstitial lung disease, and drug delivery. Real-world studies examine tofacitinib as monotherapy or with csDMARDs and identify factors associated with discontinuation of JAK inhibitors and bDMARDs. Mechanistic comparisons address SOCS signaling, immunoproteasomes, endothelial flow-mediated dilation, and cardiometabolic effects. Sustained-release microspheres and KL-6 monitoring extend the work toward longer action and assessment of lung outcomes, without establishing a single preferred strategy.
7 papers · 63.6%
-
JAK Inhibition in Alopecia Areata
JAK inhibition is being evaluated across acute and long-standing alopecia areata, with ritlecitinib and baricitinib compared for treatment response. Disease duration is becoming a central factor in judging efficacy, including disease persisting for at least eight years. The work is moving toward treatment selection based on clinical context rather than treating alopecia areata as a uniform condition. Durability and response in chronic disease remain open questions.
2 papers · 18.2%
-
Targeted JAK Therapy in Colitis
Localized anti-inflammatory delivery is being developed for ulcerative colitis, alongside clinical testing of tofacitinib in chronic pouchitis. A hyaluronic-acid platform targets inflamed colon tissue in Dextran Sodium Sulfate models, aiming to improve exposure while limiting systemic dosing. The STOPit trial tests induction and maintenance in pouchitis through an open-label and randomized design. Clinical benefit, durability, and the value of colon targeting remain unresolved.
2 papers · 18.2%
Papers
The 11 papers from the last 6 months that study tofacitinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
JAK Therapy in Rheumatoid Arthritis (7)
- Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis. Arthritis research & therapy · 16 Sept 2026 PMID 42745343
- Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study. Respiratory medicine · 10 Sept 2026 PMID 42722091
- Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study). Clinical rheumatology · 19 Aug 2026 PMID 42616227
- Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study. Clinical rheumatology · 13 Aug 2026 PMID 42587227
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
- Deciphering in vitro-in vivo correlation of single-dose injectable sustained-release tofacitinib-loaded microspheres for long-acting anti-inflammatory therapy of rheumatoid arthritis. International journal of pharmaceutics · 27 Jul 2026 PMID 42508508
- Evaluating the cardiometabolic impact of Janus-kinase inhibition: An experimental analysis of Tofacitinib's therapeutic potential in a rodent model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jul 2026 PMID 42497584
JAK Inhibition in Alopecia Areata (2)
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study. Acta dermato-venereologica · 30 Jun 2026 PMID 42377046
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study. Acta dermato-venereologica · 26 May 2026 PMID 42186168
Targeted JAK Therapy in Colitis (2)
- An innovative colon inflammation-targeting platform for ulcerative colitis treatment. Science advances · 23 Oct 2026 PMID 42913000
- Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial. BMJ open · 17 Jul 2026 PMID 42468955
By study type
Clinical trials (2)
- Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study. Respiratory medicine · 10 Sept 2026 PMID 42722091
- Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial. BMJ open · 17 Jul 2026 PMID 42468955
Observational studies and case reports (5)
- Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis. Arthritis research & therapy · 16 Sept 2026 PMID 42745343
- Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study). Clinical rheumatology · 19 Aug 2026 PMID 42616227
- Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study. Clinical rheumatology · 13 Aug 2026 PMID 42587227
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study. Acta dermato-venereologica · 30 Jun 2026 PMID 42377046
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study. Acta dermato-venereologica · 26 May 2026 PMID 42186168
Human data, design not indexed (1)
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
Preclinical: animal, cell and lab studies (3)
- An innovative colon inflammation-targeting platform for ulcerative colitis treatment. Science advances · 23 Oct 2026 PMID 42913000
- Deciphering in vitro-in vivo correlation of single-dose injectable sustained-release tofacitinib-loaded microspheres for long-acting anti-inflammatory therapy of rheumatoid arthritis. International journal of pharmaceutics · 27 Jul 2026 PMID 42508508
- Evaluating the cardiometabolic impact of Janus-kinase inhibition: An experimental analysis of Tofacitinib's therapeutic potential in a rodent model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jul 2026 PMID 42497584
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.